Clinical Trials

ASCO, SITC Release Recommendations for Clinical Trial Reporting of Immunotherapy Adverse Events

ASCO, SITC Release Recommendations for Clinical Trial Reporting of Immunotherapy Adverse Events

By

As immunotherapies gain a stronger foothold as a treatment option for cancer, ASCO and SITC convened a panel to develop recommendations to ensure consistent and efficient clinical trial reporting in immuno-oncology.

Delphi Panel Presents Recommendations for Expanding Role of Patients in Research

Delphi Panel Presents Recommendations for Expanding Role of Patients in Research

By

A Delphi panel developed recommendations for integrating patients, as well as caregivers and advocate, a greater role in medical research while maintaining scientific integrity of studies.

ASCO Roundtable Addresses Clinical Trial Financial Burdens

ASCO Roundtable Addresses Clinical Trial Financial Burdens

By

The American Society of Clinical Oncology hosted a roundtable to develop recommendations targeted at improving patients' out-of-pocket costs for clinical trial participation.

Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma

Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma

By

A prospective TLN cohort study demonstrated that trial eligibility is a strong predictor of progression-free and overall survival among patients with multiple myeloma.

Propolis Mouthwash Treatment Effectively Eases Severe Oral Mucositis

Propolis Mouthwash Treatment Effectively Eases Severe Oral Mucositis

By

In this systematic review, investigators sought to determine the safety, effectiveness, and tolerability of propolis mouthwash in preventing severe oral mucositis in patients undergoing chemotherapy or radiotherapy.

Patient Fears of Placebo Use in Clinical Trials

Patient Fears of Placebo Use in Clinical Trials

By

What should be explained to patients regarding placebo use in controlled trials?

Cancer in Children and Adolescents (Fact Sheet)

Cancer in Children and Adolescents (Fact Sheet)

This fact sheet reviews cancer in adolescents and children, including possible causes, treatment, and the general outlook for childhood cancers.

NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes

NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes

By

A clinic staffed with clinical research nurses provided needed care for patients in clinical trials who experienced adverse effects, and also ensured consistent documentation of treatment-related AEs, according to a presentation at the 2018 ONS Annual Congress.

Clinical Research Nursing Staff an Important Part of Oncology Clinical Trial Programs

Clinical Research Nursing Staff an Important Part of Oncology Clinical Trial Programs

By

The importance of oncology clinical research nurses in the clinical trial process was explored in a study presented at the 2018 ONS Annual Congress.

Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers

Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers

By

A newly developed web site, described in a presentation at the 2018 ONS Annual Congress, aims to help nurses and patients explore clinical trial options for patients with hematologic cancers.

Individual Meaning-Centered Psychotherapy May Improve Distress in Advanced Cancer

Individual Meaning-Centered Psychotherapy May Improve Distress in Advanced Cancer

A randomized study evaluated the effectiveness of individual meaning-centered psychotherapy on psychological outcomes and spiritual well-being for patients with advanced cancer, compared with enhanced usual care or supportive psychotherapy.

Can a Smartphone App Track Patient Symptoms During Clinical Trials?

Can a Smartphone App Track Patient Symptoms During Clinical Trials?

By

Researchers explored the effectiveness of using a smartphone app to monitor adverse effects of patients with cancer undergoing treatment as part of a clinical trial.

Study Links High Travel Burden, Clinical Trial Participation

Study Links High Travel Burden, Clinical Trial Participation

By

Travel to appointments can be difficult for patients with cancer. In this study, researchers sought to determine the effect of travel burden on clinical trial participation by household income, race/ethnicity, and clinical trial phase.

Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma

Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma

By

With median age of participants in clinical trials for soft-tissue sarcoma younger than most patients who develop the disease, these researchers sought to determine the prevalence of including persons older than 65 in clinical trials and the efficacy of first-line chemotherapy for STS in older patients.

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

By

This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

By

In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.

Determining Clinical Trial Eligibility

Determining Clinical Trial Eligibility

By

How is clinical trial eligibility determined?

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

By

Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

By

Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.

Bridging the Gap in Genetic Cancer Research Data on Minority Populations

Bridging the Gap in Genetic Cancer Research Data on Minority Populations

By

Investigators sought to determine why so few biospecimens were available for research from minority populations of women with breast cancer.

Current Findings in Trial Evaluating Paclitaxel Substitution in Invasive Breast Cancer

Current Findings in Trial Evaluating Paclitaxel Substitution in Invasive Breast Cancer

By

Researchers presented an update of findings in the GeparSepto trial, which seeks to determine whether improvements in pathologic complete response can be translated to a survival benefit, at SABCS 2017.

Novel Predictive Model More Effectively Identifies Risk for Lung Cancer

Novel Predictive Model More Effectively Identifies Risk for Lung Cancer

By

PanCan study results demonstrate the effectiveness of a novel predictive model in identifying risk of lung cancer in patients who do not meet the screening criteria of other models, including those used in the NLST.

Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP

Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP

By

Previous studies determined the effectiveness of 6 months of therapy with eltrombopag in patients with ITP. In this analysis, researchers extended 4 clinical trials to assess efficacy and safety of eltrombopag therapy for more than 6 months in patients with ITP.

New Class of Clinical Trial Enhances Research on Cancer Care Delivery

New Class of Clinical Trial Enhances Research on Cancer Care Delivery

By

What is a CCDR clinical trial and how does it differ from clinical trials that test new drugs?

Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC

Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC

By

Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.

High Rates of Adverse Events Lead to Earlier Dropouts in Phase 1 Cancer Trials

High Rates of Adverse Events Lead to Earlier Dropouts in Phase 1 Cancer Trials

By

Phase 1 trials are used to determine the safety profiles of treatment regimens. In this retrospective review, investigators sought to understand the reasons participants in these studies drop out.

Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma

Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma

By

The first interim analysis of the ENDEAVOR trial reported superiority of carfilzomib in some outcomes; however, data on overall survival were not available. This second interim analysis reports on overall survival with carfilzomib for patients with relapsed/refractory multiple myeloma.

More Patients Enrolled in Cancer Trials Under ACA

More Patients Enrolled in Cancer Trials Under ACA

Insurer approval rates rose from 85 percent before Affordable Care Act to 95 percent after the health care bill was enacted.

Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics

Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics

By

An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.

Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer

Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer

By

Results of a phase 2 clinical trial of savolitinib, a highly selective small molecule inhibitor of c-Met, found the agent was active and tolerable in patients with Met-driven advanced or metastatic papillary renal cell carcinoma (PRCC).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs